Vaxcyte, Inc. PCVX Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Vaxcyte, Inc.'s accrued liabilities, current?
- Vaxcyte, Inc. (PCVX) reported accrued liabilities, current of $30.25M in Q1 2026.
- How has Vaxcyte, Inc.'s accrued liabilities, current changed year-over-year?
- Vaxcyte, Inc.'s accrued liabilities, current increased by 16.1% year-over-year, from $26.04M to $30.25M.
- What is the long-term trend for Vaxcyte, Inc.'s accrued liabilities, current?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s accrued liabilities, current has grown at a 52.5% compound annual growth rate (CAGR), from $3.77M to $31.07M.